Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
BLCO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.16 - $21.69
Previous CloseN/A
Volume107.99K
Average Volume (3M)647.45K
Market Cap
$4.98B
Enterprise Value$11.05B
Total Cash (Recent Filing)$305.00M
Total Debt (Recent Filing)$4.78B
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Apr 30, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding352,470,800
10 Day Avg. Volume708,395
30 Day Avg. Volume647,454
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.14
Price to Cash Flow (P/CF)62.30
P/FCF Ratio49.00
Enterprise Value/Market Cap2.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.81
Enterprise Value/Ebitda18.20
Forecast
1Y Price Target
$18.50Price Target Upside30.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Market LeadershipBausch + Lomb would remain as the leader of prescription DED drugs in the coming quarters.
Product PerformanceSiHy Dailies posted highly impressive revenue growth in 2024, maintaining the view that it can drive total BLCO revenue growth in 2025.
Revenue GrowthThe company continued to deliver revenue growth across all three segments in 4Q24: Vision Care revenue was $723M with 9% YoY growth; Surgical revenue was $231M with 13% YoY growth; and Pharmaceuticals revenue was $326M with 6% YoY growth.
Bears Say
Financial PerformanceThe recall is expected to have a negative impact on Q1 earnings and likely result in lower full year guidance because premium IOLs were a key growth driver for 2025.
Investor SentimentBLCO is down 10% since the announcement that BLCO was unlikely to get acquired.
Product RecallBausch & Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to a small number of cases of toxic anterior segment syndrome.
---
Ownership Overview
0.53% Insiders
0.32% Mutual Funds
7.11% Other Institutional Investors
91.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $13.16 and its highest was $21.69 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $4.98B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Apr 30, 2025 which is in 29 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Feb 19, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.03.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 352,470,800 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.25 in its last earnings report, beating expectations of $0.23. Following the earnings report the stock price went down -0.306%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
---
Bausch + Lomb Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (30.93% Upside)
$18.50 (30.93% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.32%
12-Months-Change
Fundamentals
Return on Equity
-4.76%
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
---
BLCO Company Deck
---
BLCO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Bausch + Lomb's strong revenue growth across segments, successful product launches, and substantial innovation in their R&D pipeline. Despite challenges from currency headwinds and the Inflation Reduction Act, the company maintains a positive outlook with strategic investments in key products and technologies. The sentiment is largely positive with a focus on sustained growth and innovation.Read More>---
BLCO Stock 12 Month Forecast
Average Price Target
$18.50
▲(30.93% Upside)
Technical Analysis
Best Analysts Covering BLCO
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+9.08%
reiterated a sell rating 6 days ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +9.08% per trade.
---